Hematology

The Pharmacy Times® Hematology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of blood disorders, include blood and bone marrow cancers, anemia, hemophilia, blood-clotting disorders, and leukemia.

Study: 1 in 4 Families of Children With Acute Lymphoblastic Leukemia Face Food Insecurity

September 19, 2022

Article

Receiving benefits from the SNAP program does not alleviate the issue, according to the analysis.

New NCCN Patient Guidelines for Marginal Zone Lymphoma Helps Patients, Caregivers Understand Rare Form of Blood Cancer

September 19, 2022

Article

Management of marginal zone lymphoma was impacted by the COVID-19 pandemic because some treatment options can reduce B-cell-produced antibodies.

FDA Grants Priority Review to Efanesoctocog Alfa for Individuals With Hemophilia A

September 07, 2022

Article

The agency’s decision data for the investigational factor VIII therapy from Sanofi and Soba is set for February 28, 2023.

FDA Approves Stimufend, Biosimilar for Pegfilgrastim-fpgk

September 07, 2022

Article

The biosimilar is expected to be launched as a prefilled syringe in early 2023.

Study: New Factors Are Associated With Increased PFS from BCMA-Targeted T-Cell Therapy

September 07, 2022

Article

A high proportion of myeloid cells may contribute to recurrence in those with long progression-free survival by promoting cancer growth and/or suppressing antitumor immunity.

Phase 2 Study Investigating Milvexian Met Primary Endpoints for Thromboembolic Diseases

September 01, 2022

Article

The phase 2 AXIOMATIC trials assessing milvexian met its primary endpoints, with researchers anticipating a phase 3 trial to come within the year.

Daily OTC Pearl: BleedCEASE

September 01, 2022

Article

BleedCEASE is intended to stop bleeding from cuts and nosebleeds.

Daily Medication Pearl: Tranexamic Acid

August 30, 2022

Article

Tranexamic acid indicated for patients with hemophilia for short-term use to reduce or prevent hemorrhage and decrease the need for replacement therapy during and following tooth extraction.

FDA Approves Ibrutinib for Pediatric Patients With Chronic Graft-Versus-Host Disease

August 25, 2022

Article

Ibrutinib (Imbruvica) is the first therapy to gain FDA approval for younger patients who had no prior treatment options for chronic graft-versus-host disease.

Daily Medication Pearl: Betibeglogene Autotemcel (Zynteglo)

August 25, 2022

Article

Zynteglo is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell transfusions.